WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has provided an update on the commercial strategy for its flagship product YCANTH, a treatment for molluscum contagiosum. The company reported strong progress in increasing demand and advancing its product pipeline.
The fourth quarter of 2024 saw a notable rise in dispensed applicator units, already surpassing the previous quarter. This growth occurred alongside significant cost reductions in sales and operations infrastructure, demonstrating the effectiveness of Verrica’s focused commercial efforts.
To meet growing demand, Verrica plans to introduce a single applicator configuration for YCANTH in the first quarter of 2025. This packaging update aims to reduce acquisition costs for healthcare providers, simplify same-day patient treatments, and expand access through independent pharmacies and healthcare networks.
“We are executing effectively on our commercial strategy for YCANTH,” said Jayson Rieger, PhD MBA, President and CEO of Verrica. “We’re growing the business while prioritizing value-driven spending and eliminating inefficiencies. These efforts have also led to a reduction in inventory levels among our distribution partners.”
Verrica remains committed to expanding its pipeline, which includes products for the treatment of common warts and basal cell carcinoma. Preliminary data from a Phase 2 study highlights the potential of VP-315, an oncolytic peptide, as a novel treatment for basal cell carcinoma. Meanwhile, YCANTH is being developed for common warts in partnership with Torii Pharmaceutical, targeting an unmet need in dermatology.
“With favorable demand dynamics for YCANTH and advancements in our pipeline, we are positioned for a strong 2025,” Rieger added. “Our recent financing has bolstered our balance sheet, and operational efficiencies will further preserve our resources as we continue to build a more focused and efficient commercial-stage company.”
This update highlights Verrica’s progress in innovation and patient accessibility in dermatology treatments.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.